Gallbladder Cancer – Pipeline Review, H2 2016
Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.
Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gallbladder Cancer.
Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Gallbladder Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Gallbladder Cancer – Overview 7
Pipeline Products for Gallbladder Cancer – Comparative Analysis 8
Gallbladder Cancer – Therapeutics under Development by Companies 9
Gallbladder Cancer – Therapeutics under Investigation by Universities/Institutes 10
Gallbladder Cancer – Pipeline Products Glance 11
Clinical Stage Products 11
Gallbladder Cancer – Products under Development by Companies 12
Gallbladder Cancer – Products under Investigation by Universities/Institutes 13
Gallbladder Cancer – Companies Involved in Therapeutics Development 14
4SC AG 14
harma Inc 14
BeiGene Ltd 16
Eli Lilly and Company 17
Novartis AG 18
VasGene Therapeutics Inc 19
Gallbladder Cancer – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
BGBA-317 – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
binimetinib – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology – Drug Profile 38
Product Description 38
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: